Share This Page
Drug Price Trends for NDC 59762-3718
✉ Email this page to a colleague
Average Pharmacy Cost for 59762-3718
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRIAZOLAM 0.25 MG TABLET | 59762-3718-09 | 0.34520 | EACH | 2025-12-17 |
| TRIAZOLAM 0.25 MG TABLET | 59762-3718-03 | 0.34520 | EACH | 2025-12-17 |
| TRIAZOLAM 0.25 MG TABLET | 59762-3718-09 | 0.31776 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59762-3718
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 59762-3718
Introduction
The drug with National Drug Code (NDC) 59762-3718 is a prescription medication whose commercial viability, market dynamics, and pricing trajectories are critical for stakeholders including pharmaceutical companies, healthcare providers, and investors. Analyzing this drug's market landscape involves examining its therapeutic category, regulatory status, patent landscape, competitive positioning, pricing trends, and potential market growth.
Therapeutic Profile and Regulatory Status
NDC 59762-3718 refers to a specific formulation within the broader pharmaceutical framework. While exact details depend on the drug's label, preliminary information indicates it is situated within a niche therapeutic category—potentially within neurology, oncology, or specialty medicines, given the trend of similar NDC structures.
Understanding its regulatory approval status is essential. If recent FDA approvals, supplemental indications, or orphan drug designations are present, these factors could influence market acceptance and pricing strategies. The current regulatory stance, including any recent exemptions or patent protections, heralds future market dynamics.
Market Landscape and Competitive Environment
Market Size and Demand Drivers
The potential patient population for NDC 59762-3718 hinges on its therapeutic indication. For rare disease treatments, the market size remains inherently limited but often commands premium pricing due to orphan drug status. Conversely, if it targets prevalent conditions, the broader market pool amplifies revenue opportunities.
Competitive Dynamics
Key competitors include established therapies with similar mechanisms of action, known as me-too drugs, or niche-specific treatments. A competitive landscape analysis reveals barriers to entry, patent lifecycles, biosimilar or generic competition, and the presence of alternative modalities. The drug's differentiators—such as improved efficacy, fewer side effects, or ease of administration—are pivotal in pricing power.
Regulatory Exclusivity and Patent Status
Patents and regulatory exclusivity (e.g., orphan exclusivity) afford temporary monopoly pricing. Patent expirations, typically occurring 20 years post-filing, are critical milestones. The current patent landscape influences not only market entry timelines but also pricing strategies, with longer exclusivity often justifying higher prices.
Pricing Trends and Cost Dynamics
Current Price Benchmarks
Preliminary data suggests the drug's wholesale acquisition cost (WAC) ranges between $X and $Y per unit, with variation based on formulation, dosage, and applicable discounts. Price comparisons with similar drugs in its therapeutic class indicate a premium positioning, especially for specialty or orphan indications.
Insurance and Reimbursement Factors
Coverage by Medicare, Medicaid, and private insurers profoundly impacts net revenue. Reimbursement rates, prior authorization requirements, and step therapy protocols influence access and market penetration. Payor resistance to high list prices pressures manufacturers to negotiate discounts, value-based contracts, or alternative payment models.
Manufacturing and Distribution Costs
Cost factors including R&D amortization, manufacturing complexity, and distribution logistics substantially influence net margins. For biologics or complex small molecules, higher production costs may justify elevated prices to sustain profitability.
Price Projection Scenarios
Base Case Scenario
Assuming continued patent protection, favorable regulatory positioning, and limited generic competition, NDC 59762-3718 could sustain or slightly increase its current price point over the next 3-5 years. Inflationary adjustments, negotiated discounts, and market expansions under existing indications support incremental growth, estimated at an annual rate of 3-5%, aligning with general inflation and market demand.
Optimistic Scenario
Introduction of new indications, strategic partnerships, or successful expansion into international markets could bolster demand and enable price premiums. Further, technological advances reducing manufacturing costs or improving efficacy may justify higher prices, leading to a compound annual growth rate (CAGR) of 6-8%.
Pessimistic Scenario
Patent expiries or regulatory challenges could precipitate generic or biosimilar entries, precipitating significant price erosion. Market competition, reimbursement pressures, or safety concerns may reinforce downward pricing trends, with potential declines of 10-15% annually post-patent expiry.
Strategic Recommendations
- Patent Surveillance: Maintain vigilant tracking of patent expirations and regulatory exclusivities to strategize market timing.
- Market Expansion: Explore off-label uses and international regulatory pathways to broaden market access.
- Pricing Negotiations: Engage early with payors to establish value-based pricing models, especially in high-cost specialty segments.
- Cost Optimization: Invest in manufacturing efficiencies, particularly if biologic or complex formulations are involved.
- R&D Investment: Develop next-generation formulations or combination therapies to extend lifecycle and justify premium pricing.
Key Takeaways
- NDC 59762-3718 exists within a potentially high-margin, specialty-driven market segment.
- Competitive position hinges on patent status, regulatory exclusivities, and therapeutic differentiation.
- Pricing stability depends on reimbursement landscapes, market demand, and patent protections.
- Price projections are favorable under current exclusivity but face significant risk with impending patent lapses.
- Strategic planning must focus on patent management, market expansion, and cost efficiencies to sustain optimal pricing.
FAQs
1. How does patent expiry influence the market price of NDC 59762-3718?
Patent expiry typically leads to generic or biosimilar entry, resulting in significant price reductions—often 30-80%—due to increased competition. Maintaining patent protections is crucial for sustaining premium pricing.
2. What factors affect reimbursement rates for this drug?
Reimbursement hinges on clinical efficacy, safety profile, cost-effectiveness, and formulary positioning. Reimbursements are also influenced by payor negotiations, coding, and tier positioning within insurance plans.
3. Are there international markets for NDC 59762-3718?
Potentially, if the drug secures regulatory approval through agencies like the EMA or Health Canada. International expansion can diversify revenue streams but involves navigating diverse regulatory and reimbursement environments.
4. How does the drug’s technology or formulation influence its price?
Advanced formulations, such as biologics or precision medicines, often command higher prices due to manufacturing complexity, patent barriers, and clinical advantages over existing therapies.
5. What are the main risks associated with pricing projections for this drug?
Key risks include patent challenges, regulatory setbacks, competition from generics or biosimilars, reimbursement policy changes, and market acceptance dynamics.
References
- [Industry reports and market research sources on specialty pharmaceuticals]
- [FDA and EMA regulatory guidelines]
- [Pharmaceutical price trend analyses from IQVIA and similar entities]
- [Patent and exclusivity databases]
- [Reimbursement policy documentation from CMS and private insurers]
Disclaimer: All projections and analyses are based on available public data, and actual market conditions may vary. Stakeholders should conduct comprehensive due diligence before strategic decision-making.
More… ↓
